Shares of RegeneRx Biopharmaceuticals Inc. (OTCMKTS:RGRX – Get Free Report) passed above its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $0.01 and traded as high as $0.1730. RegeneRx Biopharmaceuticals shares last traded at $0.1730, with a volume of 50 shares trading hands.
RegeneRx Biopharmaceuticals Price Performance
The business has a 50-day simple moving average of $0.01 and a two-hundred day simple moving average of $0.01.
RegeneRx Biopharmaceuticals Company Profile
RegeneRx Biopharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing regenerative medicine products based on thymosin beta 4, a naturally occurring peptide that the company believes may support tissue protection, repair and healing.
The company’s lead product candidate is RGN-259, a preservative-free topical ophthalmic solution being developed for certain ocular surface disorders, including neurotrophic keratopathy and dry-eye-related conditions. RegeneRx has also investigated other thymosin beta 4-based candidates, including RGN-137, a topical gel for wound-healing applications, and RGN-352, an injectable formulation intended for systemic tissue-repair indications.
RegeneRx has historically pursued its products through clinical development programs and collaborations or licensing arrangements with regional pharmaceutical partners.
Featured Stories
- Five stocks we like better than RegeneRx Biopharmaceuticals
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for RegeneRx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
